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FOR THE VADT STUDY GROUP
OBJECTIVE — Bloodpressurerangesassociatedwithcardiovasculardisease(CVD)eventsin
advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and
follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP
combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT).
RESEARCH DESIGN AND METHODS — Participants in the VADT (n  1,791) with
hypertension received stepped treatment to maintain blood pressure below the target of 130/80
mmHginstandardandintensiveglycemictreatmentgroups.Bloodpressurelevelsofallsubjects
at baseline and On-Study were analyzed to detect associations with CVD risk. The primary
outcome was the time from randomization to the ﬁrst occurrence of myocardial infarction,
stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, am-
putation for ischemic gangrene, or CVD death.
RESULTS — Separated SBP 140 mmHg had signiﬁcant risk at baseline (hazards ratio [HR]
1.508,P0.001)andOn-Study(HR1.469,P0.002).DBP70mmHgincreasedCVDevents
at baseline (HR 1.482, P  0.001) and On-Study (HR 1.491, P  0.001). Combined blood
pressure categories indicated high risk for CVD events for SBP 140 with DBP 70 mmHg at
baseline(HR1.785,P0.03)andOn-Study(HR2.042,P0.003)andnearlyallSBPwithDBP
70 mmHg.
CONCLUSIONS — Increased risk of CVD events with SBP 140 mmHg emphasizes the
urgencyfortreatmentofsystolichypertension.IncreasedriskwithDBP70mmHg,evenwhen
combinedwithSBPinguideline-recommendedtargetranges,supportsanewﬁndinginpatients
with type 2 diabetes. The results emphasize that DBP 70 mmHg in these patients was associ-
ated with elevated CVD risk and may best be avoided.
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B
ased on results of recent interven-
tional trials (1–3), the question of
whether or not intensive glucose
control signiﬁcantly reduces the risk of
cardiovascular disease (CVD) in all pa-
tients with type 2 diabetes remains con-
troversial. It may be beneﬁcial in
subgroups of these patients when severe
hypoglycemia is avoided. Blood pressure
(BP) control is consistently correlated
with CVD events in studies of risk factors
in type 2 diabetes. In the UK Prospective
Diabetes Study, BP control was twice as
effective as glucose control in preventing
anydiabetesendpoints(4,5).TheHyper-
tension Optimal Treatment (HOT) study
and the Appropriate Blood Pressure Con-
trol in Diabetes (ABCD) trial support im-
proved BP control as a signiﬁcant CVD
event preventive factor in patients with
diabetes(6–8).BoththeAmericanDiabe-
tes Association (ADA) and the Joint
National Committee on Prevention, De-
tection, Evaluation, and Treatment of
HighBloodPressure(JNC-7)recommend
treatment of BP in patients with diabetes
to a target of 130/80 mmHg (9,10).
Current evidence supports a systolic
blood pressure (SBP) level of 140
mmHg, but there is sparse information to
guidephysiciansastohowfartheSBPand
diastolic blood pressure (DBP) can be
lowered safely and whether lower BP lev-
els might be associated with increased
risk. We analyzed the BP data collected
during the Veterans Affairs Diabetes Trial
(VADT) to learn whether speciﬁc levels of
BPinpatientswithtype2diabetespredict
CVD events.
The VADT is a 20-center 1,791-
patientprospectivestudyofintensivever-
susstandardglucosetreatmentinpatients
with suboptimal responses to maximum
oral agents or insulin. The main objective
was to assess the beneﬁt of intensive glu-
cose control for up to 7 years on CVD
events in patients with advanced type 2
diabetes. Other objectives included the
assessmentoftheeffectsonmicrovascular
and neurological complications, cogni-
tive function, quality of life, and cost-
effectiveness. BP, lipids, diet, and lifestyle
were treated identically in both arms. By
improvingBPcontrolinanidenticalman-
nerinbothglucosearms,VADTexcluded
the effect of BP differences in CVD events
between treatment arms and reduced the
overall risk of macrovascular complica-
tions during the trial. The initial results
were published recently (1).
RESEARCH DESIGN AND
METHODS— Randomization for
VADT began in 2000. In all, 1,791 indi-
viduals were included in the study. The
design of VADT and the results have been
reported elsewhere (1,11). Baseline char-




who entered the trial with new or treated
hypertension were given stepped treat-
ment to maintain BP below 130/80
mmHg.AfterstartingwithACEinhibitors
or angiotensin II receptor blockers, the
following agents were added as needed:
diuretics, cardioselective -blockers, cal-
cium channel blockers, clonidine, hy-
dralazine, and minoxidil. The primary
outcome was the time from randomiza-
tion to the ﬁrst occurrence of myocardial
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ure, surgery for vascular disease, inoper-
able coronary disease, amputation for
ischemic gangrene, or CVD death. This
study was approved by the Institutional
Review Boards of each participating site,
and all subjects gave informed consent.
Deﬁnition of BP categories
The ADA and JNC-7 target BP levels de-
ﬁned desirable measurements (9,10).
Thus, 105–129/70–79 mmHg was con-
sidered the optimal target BP, 130–139
mmHg SBP as above target, and 140
mmHg as systolic hypertension among
patients with type 2 diabetes. DBP 80
mmHg was above target and included pa-
tients with diastolic prehypertension
(80–89 mmHg) and diastolic hyperten-
sion (90 mmHg). Low BP was deﬁned
as105/70mmHg(12,13).TheJNC-7
category of SBP prehypertension (120–
139 mmHg) was used in selected addi-
tional analyses.
Statistical analysis
Two sets of analyses using Cox propor-
tionalhazardmodels(SAS,version9.2for
Windows; SAS Institute, Cary, NC) were
performed to assess BP as a predictor of
time to ﬁrst CVD event. Baseline-only
measurements of SBP and DBP were used
as covariates to predict time to ﬁrst CVD
event. Three baseline BP models were ﬁt-
ted: continuous SBP and DBP, categorical
SBP and DBP separately, and categorical
SBP and DBP cross-combinations. These
models were useful in determining which
level of baseline BP was predictive of the
time to ﬁrst CVD event. Next, both base-
line and quarterly BP measures were used
astime-varying(deﬁnedasOn-Study)co-
variates in proportional-hazard models of
time to ﬁrst CVD event, including the
subgroup analysis of the composite CVD
end point risk associated with separate
SBP and DBP. For the On-Study analysis,
any missing BP data were imputed with
the last observation carried forward. The
samethreemodelsmentionedabovewere
ﬁtted with the time-varying BP data. The
derived effects of BP on risk of event were
an estimate of the effect of the BP level at
thetimeofagivenCVDevent,ratherthan
the BP at baseline. Hazard ratios (HRs),
95% CIs, and P values are reported. HRs
are interpreted as percent increased risk
per mmHg increase for continuous mod-
els and percent increased risk compared
with the given reference category for cat-
egorical models.
RESULTS— At baseline, the mean age
was 60.4  8.7 years, BMI was 31  4
kg/m
2,A1Cwas9.41.5%,anddiabetes
duration was 11.5  7.5 years (mean 
SD). Of the patients, 40% had prior CVD
events.MeanBPwas132/76mmHg(sup-
plementary Table 1). The cohort entering
VADT had near-optimal mean BP. This
was further reduced within 1 year and
was maintained below target for up to 7
years with added BP treatment (1).
Separate BP components and
interaction of BP components (SBP
and DBP) as continuous variables at
baseline and 7 years On-Study
All patients in both the standard and in-
tensive treatment groups were included
in the analyses, regardless of BP medicine
treatment, to facilitate the ability to pre-
dict CVD event risk associated with BP.
An initial analysis of the continuous SBP
and DBP as separate components along
with the interaction of SBP and DBP com-
ponents was done to test whether there
was an association between the BP read-
ings and primary outcomes. The contin-
uous SBP, DBP, and interaction of
components (SBP  DBP) was signiﬁcant
both at baseline (P  0.02, P  0.001,
and P  0.001, respectively) and On-
Study (P  0.002, P  0.001, and P 
0.001, respectively). These analyses dem-
onstrated signiﬁcant likelihood estimates
that SBP alone, DBP alone, and their in-
teraction were related to the risk of CVD
events. We further investigated the read-
ings as separate SBP and DBP categorical
components and as combined SBP and
DBP categorical components to deter-
mine what range of BP would be associ-
ated with signiﬁcant risk of CVD events.
BP categories
Hypertension, deﬁned as current treat-
mentforhypertensionoraBPof140/90
mmHg, was present in 72% of patients
(1). BP ranges and numbers of patients in
each category are listed in Table 1. Cate-
gories were chosen to be in accord with
ADA and JNC-7 treatment target levels
(9,10). With the designation of prehyper-
tension (SBP 120–139 mmHg/DBP
80–89 mmHg), there was some overlap
of systolic prehypertension with our tar-
get range of 105–129/70–79 mmHg (9).
Separate SBP and DBP components
as categorical variables at baseline
and On-Study
To further characterize which BP ranges
might be associated with signiﬁcant risks
for CVD events, we selected a range of
separate SBP and DBP measurements to
evaluate. Of note, at baseline and On-
Study, there were expected signiﬁcant in-
creased risks for CVD for SBP 140
mmHg. SBP levels of 130–139 mmHg
both at baseline and On-Study were not
associated with increased risk (Table 2).
In a separate analysis of the single BP
components with different BP ranges,
neither systolic (120–129 mmHg and
130–139 mmHg) nor diastolic prehyper-
tension (80–89 mmHg) ranges were as-
sociated with signiﬁcant increased risks
for CVD events in this population (sup-
plementary Table 2). Subgroup analysis
of the composite end point indicated that
myocardial infarction, congestive heart
failure, cardiovascular death, and periph-
eral revascularization showed signiﬁcant
increased risk both at SBP 140 mmHg
and DBP 70 mmHg. Amputation had
signiﬁcant increased risk only at 140
mmHg. Coronary revascularization, in-
operable CAD, and stroke did not show
signiﬁcant increased risk at these BPs
(supplementary Table 3). A crucial ﬁnd-
ingatbothbaselineandOn-Studywasthe
signiﬁcant increased risk for CVD associ-
ated with a DBP 70 mmHg. In the gen-
eral population, an increased CVD risk
has been reported for a DBP 70 mmHg,
but a speciﬁc cutoff level of DBP has not
been identiﬁed or reported (13,14).
Our evaluation of separate SBP and
DBP measurements as categorical vari-
Table 1—Baseline BP categories for the entire population
SBP
105 105–129 130–139 140 All
DBP
70 44 294 64 44 446
70–79 19 359 174 127 679
80 —* 151 170 337 658
All 63 804 408 508 1,783
Data are n. *No patients in this category.
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cant increased risk of CVD at SBP 140
mmHg and DBP 70 mmHg when each
BP category was analyzed in comparison
with the target ranges. Combinations of
two continuous variables (SBP and DBP)
noted previously were also signiﬁcant,
which indicated that the effect of an in-
creasing SBP depended on the level of
DBP. Evidence from the Framingham
Heart Study supported the combined BP
components versus single components as
superior for predicting CVD risk in the
general population (14).




to determine their utility in predicting
CVDeventinourpatients(Table3).Con-
sistent with the single component mea-
sures, both baseline and On-Study SBP
140mmHgincreasedtheriskforaCVD
eventacrossallcategoriesofDBP.Atbase-
line, there was signiﬁcant risk of CVD
event for the DBP 70 mmHg associated
with each SBP range and an increase in
the HR with nonsigniﬁcance for the
105 mmHg range (HR 1.609, P 
0.09, Table 3).
On-Study, DBP 70 mmHg was as-
sociated with signiﬁcant increased risk at
anySBPrangeexceptfor130–139mmHg
(Table3).AtbothbaselineandOn-Study,
the BP range of 70–79 mmHg was not
associated with a signiﬁcant increase in
risk with SBP 140 mmHg (Table 3).
With DBP 80 mmHg, there was no sig-
niﬁcant risk increase with corresponding
SBP ranges 140 mmHg at baseline and
On-Study. Overall, with both BP compo-
nents included at baseline and On-Study,
the ranges of 105–129/70, 140/70,
140/70–79, and 140/80 mmHg
represented ranges associated with signif-
icant increased risks for CVD events in
this population (Table 3). Finally, with
DBP 70 mmHg, HRs were increased
concordantly at baseline and On-Study,
regardless of SBP levels.
Low DBP level investigation
An additional goal was to identify a po-
tential cutoff for DBP 70 mmHg that
had signiﬁcant increased risk for CVD
events. The Framingham Heart Study
noted signiﬁcant increased CVD risk in
the adult general population with DBP
70 mmHg combined with SBP of 120–
129 mmHg (HR 2.0), 130–139 mmHg
(HR 1.9), and 140–159 mmHg (HR 3.0)
(14). There was no deﬁnition of the lower
limit of DBP before additional increased
risk might occur. The European Guide-
linesforHypertensionassignanincreased
risk to DBP of 60–70 mmHg (13). A fur-
therdivisionoftheDBPrangesinoursin-
gle-component BP analyses showed
signiﬁcant increased risk for DBP 60
and 60–69 mmHg, at baseline (HR
2.139, P  0.001; HR 1.361, P  0.02,
respectively) and On-Study (HR 2.155,
P  0.001; HR 1.310, P  0.02, respec-
tively). To explore the potential cutoff
level further, we carried out sensitivity
analyses of the combined BP ranges by
testing DBP 65 and 60 mmHg with
the associated target BP ranges reviewed
previously. Because of the smaller num-
berofpatientswithSBP130mmHg,we
were able to apply this analysis to only
two groups of SBP ranges: SBP 105
mmHg and SBP 105–129 mmHg. Based
on the sensitivity analysis, there were
threeinterestingﬁndings.First,inthetar-
get SBP/DBP group (105–129/65
mmHg), the risk and signiﬁcance re-
mainedsimilaratbaseline(HR1.453,P
0.02) and On-Study (HR 1.557, P 
0.001). We did not explore this group
further because statistical signiﬁcance did
not change with the different levels of
DBP. Second, when the group with SBP
105 mmHg was examined with differ-
ent DBP ranges, the HR and signiﬁcance
increased at baseline. With DBP 65
mmHg, the results were similar to 70
mmHg (HR 1.575, P  0.14). However,
with DBP 60 mmHg, the risk increased
signiﬁcantly (HR 2.903, P  0.004). This
implied that the cutoff point of DBP for
further increased CVD risk was 60
mmHg with SBP 105 mmHg at base-
line. Finally, the On-Study HR increased
briskly with DBP 60 mmHg. When the
DBP level was tested at 70, 65, and
60 mmHg, the HR increased from
2.103 to 2.198, and then to 2.825, re-
spectively, while the P values remained
Table 2—HRs for separated SBP and DBP categories relative to each reference category at
baseline and On-Study
Baseline On-Study
HR 95% CI P HR 95% CI P
DBP (mmHg)
70–79 Reference Reference
70 1.482 1.179–1.862 0.001 1.491 1.206–1.844 0.001
80 1.030 0.825–1.287 0.79 1.049 0.814–1.351 0.71
SBP (mmHg)
105–129 Reference Reference
105 0.974 0.591–1.603 0.92 1.364 0.977–1.904 0.07
130–139 1.004 0.786–1.283 0.97 0.938 0.733–1.201 0.61
140 1.508 1.203–1.890 0.001 1.469 1.157–1.867 0.002
Table 3—HRs for combined SBP and DBP categories relative to a reference category at
baseline and On-Study
Baseline On-Study
BP (mmHg) HR 95% CI P HR 95% CI P
105–129/70–79 Reference Reference
105/70 1.609 0.930–2.787 0.09 2.103 1.437–3.079 0.001
105–129/70 1.370 1.019–1.843 0.04 1.472 1.121–1.934 0.006
130–139/70 1.682 1.061–2.667 0.03 1.379 0.908–2.096 0.13
140/70 1.785 1.060–3.004 0.03 2.042 1.276–3.269 0.003
105/70–79 0.441 0.109–1.790 0.25 0.633 0.156–2.574 0.52
130–139/70–79 0.871 0.592–1.281 0.48 0.942 0.632–1.404 0.77
140/70–79 1.495 1.033–2.164 0.03 1.486 1.005–2.198 0.05
105/80* 3.273 0.455–23.55 0.24
105–129/80 0.939 0.634–1.393 0.76 1.011 0.655–1.562 0.96
130–139/80 0.983 0.675–1.432 0.93 0.957 0.611–1.497 0.85
140/80 1.499 1.130–1.990 0.005 1.536 1.104–2.137 0.01
*Insufﬁcient number in this BP category at baseline for analysis.
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results supported the conclusion that a
DBP of 70 mmHg is the level at which
CVD risk begins to increase signiﬁcantly,
with further enhanced signiﬁcant risks
withDBP60mmHgatbaselineandOn-
Study in these patients with type 2
diabetes.
CONCLUSIONS — When the VADT
BP data were analyzed with respect to the
target BP (105–129/70–79 mmHg), SBP
140 mmHg, as a single component and
combined with any DBP, indicated an in-
creased risk for CVD events in these type
2 diabetic patients at baseline and On-
Study. The results underlined the need
for treatment of type 2 diabetic patients
with SBP 140 mmHg and elevated DBP
into the target range as recommended in
ADA and JNC-7 BP guidelines (9,10). Pa-
tients in VADT with high SBP and low
DBP were at increased risk for CVD
events.
Our results support the identiﬁcation
of a new category of high CVD event risk
for the group of type 2 diabetic patients
with low DBP. Single component and
combined SBP and DBP analyses both
identiﬁed DBP 70 mmHg as a signiﬁ-
cant increased risk for primary outcomes
both at baseline and On-Study (Tables 2
and 3). Further breakdown of the DBP
levels as a single component showed a
DBP of 60–69 mmHg with signiﬁcant in-
creased risks at baseline and On-Study
(supplementary Table 2). In the same
analyses,thesingle-componentDBP60
mmHg was associated with the highest
risk (supplementary Table 2). The sepa-
rate analysis of DBP combined with SBP
highlighted 60 mmHg as the DBP with
the highest signiﬁcant risk of CVD events
at baseline and On-Study. Combined BP
components of 105/60 mmHg har-
bored the greatest increased risk at base-
line(HR2.903,P0.004)andOn-Study
(HR 2.825, P  0.001). Our ﬁndings re-
garding DBP support the Framingham
Heart Study, which identiﬁed DBP 70
mmHg associated with isolated systolic
hypertension and prehypertension as
high-riskcategoriesforCVDeventsinthe
population in which 2.3% had diabetes
(14). The European guidelines also noted
that a DBP of 60–70 mmHg should be
regarded as an additional risk when asso-
ciated with isolated systolic hypertension
(13). Our results extend the high-risk
DBP designation to our population of pa-
tients with type 2 diabetes. We identify a
DBP of 70 mmHg as the cutoff for del-
eterious levels of DBP and a DBP 60
mmHg as a likely cutoff associated with
even greater signiﬁcant risks for CVD
events.
Combined components of SBP and
DBPprovidedmorespeciﬁcBPcategories
for determination of CVD risk with base-
line only and On-Study measurements.
BP levels associated with the increased
riskwereconsistentbetweenbaselineand
On-Study measurements. We found that
the risk of CVD events increased at SBP
140 mmHg and low extremes of DBP
70 mmHg when the two components
werecombined(Table3).Ourresultsthat
certain levels of BP components analyzed
incombinationareassociatedwithhigher
CVD event risks are similar to the Fra-
mingham Heart Study ﬁndings (14). The
informationaboutbaselineandOn-Study
BP risk categories will heighten physician
awareness toward patients who need im-
mediate and continuing BP treatment.
The broad SBP and DBP target range of
130/80 mmHg (9) and the wide nor-
mal range of 120/80 mmHg lack de-
ﬁned lower limits (10,13). Our results
raise awareness of the increased CVD risk
ofDBP70mmHgwith105–129/70–79
mmHg as a reasonable BP target range for
patients with type 2 diabetes.
IntheVADTpatients,anSBPof130–
139 mmHg and a DBP of 80–89 mmHg
were better tolerated, as underscored by
the minimal changes in HRs and the lack
of signiﬁcance for these ranges whether
reviewed as individual components or
combined at baseline and On-Study (Ta-
bles 2 and 3, supplementary Tables 2 and
4). When BP components were evaluated
separately at baseline, there were no sig-
niﬁcantly increased risks associated with
DBP80mmHg(HR1.030,P0.79)or
with the SBP range of 130–139 (HR
1.004, P  0.97) (Table 2). Analysis of
speciﬁc baseline prehypertensive ranges
forDBPof80–89mmHg(HR1.071,P
0.57) and SBP ranges of 120–139 mmHg
broken down as 120–129 mmHg (HR
1.087, P  0.56) and 130–139 mmHg
(HR 1.081, P  0.61) failed to show any
signiﬁcant increases in risk (supplemen-
tary Table 2). The same DBP and SBP
ranges On-Study did not show signiﬁcant
increases in CVD event risk (supplemen-
tary Table 2). In a separate analysis of the
combined BP components at baseline,
SBP in the prehypertensive ranges (120–
129 and 129–130 mmHg) were associ-
ated with increased risk only when
combined with a DBP 70 mmHg (sup-
plementary Table 4). There were no sig-
niﬁcant increases in CVD event risk when
a DBP 80 mmHg was combined with
SBP120–129mmHgor130–139mmHg
On-Study (supplementary Table 4).
These nonintuitive ﬁndings conﬂict
with reported increased CVD risk associ-
ated with these SBP and DBP levels in
adult general populations (13,14). One
contributingfactorforthisdifferencemay
be that many patients with BPs within
these ranges already were on treatment
with antihypertensive agents resulting in
a decreased number. Patients with type 2
diabeteswhoaresimilartoVADTpatients
may tolerate more generous SBP (up to
139 mmHg) and DBP (up to 89 mmHg)
targetranges.Ourresultsunderscoreadi-
lemma for physicians who identify type 2
diabetic patients with mild increases in
SBP (e.g., 130–139 or 140–145 mmHg)
and DBP 60–69 mmHg. If they treat
the SBP aggressively with attendant low-
ering of DBP, the consequence could be a
shift of the patient into a higher CVD risk
category (Table 3, supplementary Table
4). Longstanding increased arterial stiff-
ness (manifested as increased pulse pres-
sure) and CVD in these patients may
render them less able to withstand vigor-
ous BP lowering.
Increased arterial stiffness is common
in the older population studied in the
VADT, and the higher CVD risk in our
patientswiththispresentationiscommon
in a large general population (14). Our
noted greater CVD risk of low DBP is un-
derestimated in current guidelines that
concentrateonthehigherextremesofSBP
and DBP. Another potential contributor
to the increased CVD risk of low DBP is
the existence of common genetic poly-
morphisms of single-nucleotide muta-
tions associated with increased CVD risk
and decreased DBP (15). This aspect will
require further investigation in our pop-
ulation. BP control to target in patients
with type 2 diabetes, with avoidance of
excessive low DBP and SBP, decreases
CVD risk. Long-term efforts to continue
BP control are warranted, since the bene-
ﬁts of improved BP are not sustained un-
less the control is maintained (16).
Majorstrengthsofthisstudyincluded
the large population with type 2 diabetes
with frequent BP monitoring and adjust-
ments for control, the longitudinal fol-
low-up for up to 7 years On-Study, and
the inclusion of a larger percentage of mi-
norities than most studies of this type. A
weakness was that the patients were not
randomized to BP control groups or BP
treatment. In addition, the results from
Anderson and Associates
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not be applicable to younger individuals
and women. In our exploratory BP cate-
gorical analyses, lack of statistical signiﬁ-
cance did not prove lack of risk.
Signiﬁcancemayhavebeenattenuatedby
low power to detect a difference due to
thesmallsamplesizeinthehigherBPcat-
egories coupled with the confounding
treatment effect of BP control during the
study. We did not look at the effects of
lowering BP in patients in this analysis. A
possible negative effect of antihyperten-
sive treatments that excessively lower
DBP must be considered. Future research
questions include whether BP control
changed outcomes for individual patients
in higher-risk SBP or DBP categories. We
also plan to investigate the potential asso-
ciations of these high-risk BP categories
with microvascular events.
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